Last reviewed · How we verify
Thiamazol
Thiamazol is a Small molecule drug developed by Dr.dr.Irma Bernadette, SpKK (K). It is currently in Phase 1 development for Hyperthyroidism.
Thiamazol is a small molecule that acts as a thyroid peroxidase inhibitor. It is used to treat conditions such as Graves' disease and hyperthyroidism, and has been studied in clinical trials for its effects on quality of life and the potential benefits of iodine supplementation.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Thiamazol |
|---|---|
| Sponsor | Dr.dr.Irma Bernadette, SpKK (K) |
| Target | Lactoperoxidase, Taste receptor type 2 member 38, Thyroid peroxidase |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
- Hyperthyroidism
Common side effects
Key clinical trials
- Methimazole in Patients With Progressive Glioblastoma (PHASE2)
- Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease (PHASE2)
- Prospective Evaluation of OptiThyDose (NA)
- A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
- Hyperthyroidism: Methimazole Plus L-carnitine and Selenium (NA)
- Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz (PHASE2)
- Efficacy of Methimazole Dosing Algorithm
- A Clinical Study of Hyperthyroidism in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thiamazol CI brief — competitive landscape report
- Thiamazol updates RSS · CI watch RSS
- Dr.dr.Irma Bernadette, SpKK (K) portfolio CI
Frequently asked questions about Thiamazol
What is Thiamazol?
What is Thiamazol used for?
Who makes Thiamazol?
What development phase is Thiamazol in?
What does Thiamazol target?
Related
- Target: All drugs targeting Lactoperoxidase, Taste receptor type 2 member 38, Thyroid peroxidase
- Manufacturer: Dr.dr.Irma Bernadette, SpKK (K) — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Hyperthyroidism
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing